Editing Antidepressant (section)

====Panic disorder====
[[Panic disorder]] is treated relatively well with medications compared to other disorders. Several classes of antidepressants have shown efficacy for this disorder, with SSRIs and SNRIs used first-line. Paroxetine, sertraline, and fluoxetine are FDA-approved for panic disorder, while fluvoxamine, escitalopram, and citalopram are also considered effective for them. SNRI venlafaxine is also approved for this condition. Unlike [[social anxiety]] and [[Post-traumatic stress disorder|PTSD]], some [[Tricyclic antidepressant|TCAs antidepressants]], like clomipramine and imipramine, have shown efficacy for panic disorder. Moreover, the [[Monoamine oxidase inhibitor|MAOI]] [[phenelzine]] is also considered useful. Panic disorder has many drugs for its treatment. However, the starting dose must be lower than the one used for major depressive disorder because people have reported an increase in anxiety as a result of starting the medication. In conclusion, while panic disorder's treatment options seem acceptable and useful for this condition, many people are still symptomatic after treatment with residual symptoms.<ref>{{cite journal|vauthors=Bighelli I, Castellazzi M, Cipriani A, Girlanda F, Guaiana G, Koesters M, Turrini G, Furukawa TA, Barbui C|title=Antidepressants versus placebo for panic disorder in adults|journal=The Cochrane Database of Systematic Reviews|volume=2018|issue=4|pages=CD010676|date=April 2018|pmid=29620793|pmc=6494573|doi=10.1002/14651858.CD010676.pub2}}</ref><ref>{{cite journal|vauthors=Bighelli I, Trespidi C, Castellazzi M, Cipriani A, Furukawa TA, Girlanda F, Guaiana G, Koesters M, Barbui C|title=Antidepressants and benzodiazepines for panic disorder in adults|journal=The Cochrane Database of Systematic Reviews|volume=2016|issue=9|pages=CD011567|date=September 2016|pmid=27618521|pmc=6457579|doi=10.1002/14651858.CD011567.pub2}}</ref><ref>{{cite journal|vauthors=Andrisano C, Chiesa A, Serretti A|title=Newer antidepressants and panic disorder: a meta-analysis|journal=International Clinical Psychopharmacology|volume=28|issue=1|pages=33–45|date=January 2013|pmid=23111544|doi=10.1097/YIC.0b013e32835a5d2e|s2cid=24967691|doi-access=free}}</ref>